Physician with stethoscope sitting and talking with patient in hosiptal lobby.

More than 200 oncologists weigh in on CAR T-Cell therapy, biosimilars and AML therapies

CONTRIBUTOR

Will Seaton Essential Insights contributor, healthcare writer

Will Seaton

Essential Insights contributor, healthcare writer

1. 2017 was a landmark year for CAR T-Cell therapy, but barriers still exist.

51% of oncologists participating in the survey saw CAR T-cell therapy as a potentially game-changing approach to cancer treatment.

51%

2. There is increasing acceptance of biosimilars, along with higher expectations of their cost savings.

Two medicine bottles: One reading Biosimilar. The other reading Reference Product.

66%

Explore the survey data

CAR T-cell therapy

Biosimilars

AML therapies

3. Treatment trends are changing with new, targeted therapies for acute myeloid leukemia patients.

85% of oncologists participating in the survey said they always perform genomic/mutational testing on AML patients.

85%

*
*
*
*
Subscribe to Essential Insights, our monthly newsletter featuring expert healthcare industry insights
*
Yes, I would like to learn more about Cardinal Health’s products and services by email. I can withdraw my consent or change my preferences by visiting Update Preferences. Visit Privacy Policy for more information about Cardinal Health’s privacy practices.